# Antimicrobial resistance (AMR) crisis ## What this driver is Antimicrobial resistance is a continuing One Health selection mechanism: bacteria, fungi, and other microbes that survive antibiotics, antifungals, and related drugs, then spread in clinics, farms, water, and households. It is not a single outbreak, not a unique Factrail death total, and not [access to essential medicines](/drivers/access-to-essential-medicines). Access is whether a quality drug arrives. This node is whether the drug still works. The legal-political core is the WHO Global Action Plan adopted as WHA68.7 (26 May 2015), the UN General Assembly high-level meeting political declaration of 21 September 2016, and the second high-level meeting declaration of 26 September 2024 (A/RES/79/2). Quadripartite FAO–UNEP–WHO–WOAH coordination is the institutional neighbourhood. A modelled “10 million deaths by 2050” line from the 2016 O’Neill review is a named scenario, not a measured series on this page. This driver is not [COVID-19 pandemic](/drivers/covid-19-pandemic), not [infectious-disease transmission](/drivers/infectious-disease-transmission) as a standing pressure, and not [pandemic preparedness](/drivers/pandemic-preparedness). Those companions can move with AMR. They do not replace it. It is not ukraine-war. It applies worldwide from at least the 2015 GAP onward, with a longer microbiological history. Veterinary growth-promotion, hospital empiric therapy, and poor diagnostics are channels, not competing slugs. ## Mechanism AMR moves welfare through named channels. First, failed first-line therapy. Third-generation cephalosporin-resistant *E. coli* bloodstream infection is the SDG 3.d.2 human-health lens. When empiric treatment fails, sepsis lengthens, last-resort carbapenems are used, and last-resort drugs select further. A resistance percentage is not a body-count. Second, agricultural and environmental selection. Routine farm use, untreated effluent, and aquaculture select the same gene families that later appear in human isolates. One Health is a mechanism, not a slogan. WOAH ANIMUSE and FAO InFARM are neighbouring official systems. They are not this meter. Third, missing diagnostics and delayed stewardship. GLASS participation grew; testing coverage still differs sharply by income. A high reported resistance share in a thin-testing country can be a surveillance artefact. The 2018 World point in the SDG series jumps; this page treats that year as a coverage-mix observation, not a proven doubling of biology. Fourth, pipeline failure and access contradiction. Reserve antibiotics are scarce in some low-income settings while Watch drugs are overused in others. The 2024 UNGA text set a target that at least 70% of human antibiotic use should be WHO Access-group. Missing Access is not a licence to invent a unique R&D coefficient. Fifth, political declaration without funded national action plans. The 2024 declaration’s catalytic-funding and 60%-of-countries-funded-plans language is a dated commitment. A commitment is not an implemented plan. Timing is years for gene spread and hours for a failed empiric dose. A later UNGA meeting in 2029 would be a new fact. It would not twin this driver. ## Evidence base The best evidence is WHA and UNGA instruments plus GLASS/SDG surveillance. WHA68.7 adopted the Global Action Plan on 26 May 2015 (https://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_R7-en.pdf). The 2016 high-level meeting political declaration is A/RES/71/3 (21 September 2016). The 2024 meeting on 26 September adopted A/RES/79/2, including a target to reduce bacterial-AMR-associated deaths 10% by 2030 against a 2019 baseline of 4.95 million associated deaths named in WHO’s readout (https://www.who.int/news/item/26-09-2024-world-leaders-commit-to-decisive-action-on-antimicrobial-resistance). That 4.95 million figure is the 2019 GRAM/Lancet associated-death estimate (Murray et al., *Lancet*, 2022). Attributable deaths in the same paper were about 1.27 million. Associated is not attributable. This page names both. The meter is the World series for SDG 3.d.2 — percentage of *E. coli* bloodstream infections resistant to third-generation cephalosporins — as republished by Our World in Data from WHO GLASS (https://ourworldindata.org/grapher/share-of-e-coli-bloodstream-infections-due-to-antimicrobial-resistant-bacteria.csv): 35.8% (2016), 32.4% (2017), 69.2% (2018), 36.6% (2019), 47.4% (2020), 39.21% (2021), 44.7% (2022). Values on this driver are that percentage divided by 100. The 2018 spike is disclosed as a likely reporting-mix break, not a proven biological doubling. GLASS 2025 later estimated 44.8% of *E. coli* BSI resistant to 3GC in its modelled 2023-era assessment; that is a neighbouring official figure, not copied onto the 2022 meter. Evidence is strongest for a signed UNGA declaration and a named SDG indicator. It is weaker for any unique 2050 death forecast. It is weakest where a political target is asked to prove a national plan was funded. ## Effect on welfare indicators This driver, when it actually runs, is a first-order channel into infection survival and a second-order channel into whether hospitals can keep using cheap first-line drugs. - [Under-five mortality rate](/indicators/ph-under-five-mortality-global): direction higher deaths when neonatal and paediatric sepsis meet resistant Gram-negatives. Horizon: days to years. Confidence: medium where blood-culture coverage exists; low where the only number is a global modelled total. The series is lower-is-better, so strengthening AMR is welfare-negative. No unique neonatal AMR integer is invented here. - [Life expectancy at birth](/indicators/health-welfare-021-life-expectancy-at-birth): direction lower period LE if resistant bloodstream infection becomes a large adult and child mortality term. Horizon: years. Confidence: low for a unique global coefficient; the GRAM associated/attributable split shows why. Strengthening AMR weakens a higher-is-better series. - [Universal health coverage service coverage index](/indicators/care-welfare-041-universal-health-coverage-uhc-service-coverage-index-2025-methodology): direction lower effective coverage when first-line drugs fail and Reserve drugs are absent. Horizon: years. Confidence: medium for the access-plus-resistance channel; this is not a twin of access to essential medicines. A PISA path does not follow. Missing coefficients stay missing. ## Interactions and contested points AMR interacts with access to essential medicines, infectious-disease transmission, [health-system capacity](/drivers/health-system-capacity), and [international health cooperation](/drivers/international-health-cooperation). Reinforcement is obvious when a thin laboratory, a Watch-heavy prescription, and farm effluent hit the same catchment. Offsetting is the claim that a 2024 UNGA target or an Access-70% slogan cancels 2019 GRAM deaths. A target is not a reversal. The strongest competing view is that SDG 3.d.2 World percentages are not a global incidence series because participating countries and testing density change year to year — especially the 2018 World point. That objection is serious. The competing defence of this node is only this: the indicator is the UN’s official human-health AMR SDG, the transformation is disclosed, and the 2018 break is named rather than smoothed away. A second competing view is that O’Neill’s 10 million-by-2050 figure, or GRAM’s 39 million cumulative to 2050 updates, should be the meter. Those are modelled forecasts. They remain named instruments. They are not this driver’s time series. Established: WHA68.7 (2015); UNGA 2016 and 2024 declarations; GLASS/SDG 3.d.2 World percentages 2016–2022 as published; GRAM 2019 associated 4.95 million vs attributable ~1.27 million as a named split. Not established: a unique Factrail death total, a smoothed 2018, or that A/RES/79/2 funded 60% of national plans. A 2029 UNGA review would be a new fact. It would not twin this driver. ## Dated facts - WHO found 97 antibacterials in clinical development but only 12 innovative agents in 2024. https://factrail.ai/facts/who-antibacterial-pipeline-97-agents-only-12-innovative-2024. - 2022: WHO published the AWaRe antibiotic book for evidence-based treatment and stewardship. https://factrail.ai/facts/who-aware-antibiotic-book-clinical-stewardship-2022. - 2022: Quadripartite One Health Joint Plan of Action made AMR one of six action tracks. https://factrail.ai/facts/quadripartite-one-health-joint-plan-amr-track-2022. - 2022: Global burden study estimated 1.27 million deaths directly attributable to bacterial AMR in 2019. https://factrail.ai/facts/lancet-global-bacterial-amr-burden-2019-published-2022. - 2019: WHO expanded AWaRe antibiotic classification and set a 60% Access-group target. https://factrail.ai/facts/who-aware-classification-60-percent-access-target-2019. - 2019: UN interagency group presented No Time to Wait on drug-resistant infections. https://factrail.ai/facts/un-iacg-no-time-to-wait-amr-report-2019. - WHO reported only 51 antibiotics in clinical development in its 2017 pipeline review. https://factrail.ai/facts/who-antibacterial-pipeline-51-antibiotics-september-2017. - 2017: WHO published a priority list of drug-resistant pathogens for antibiotic research. https://factrail.ai/facts/who-priority-pathogens-list-february-2017. - 2016: UN General Assembly held its first high-level meeting on antimicrobial resistance. https://factrail.ai/facts/un-high-level-amr-meeting-political-declaration-2016. - 2015: WHO launched GLASS to standardize global antimicrobial-resistance surveillance. https://factrail.ai/facts/who-glass-launched-october-2015. - 2015: World Health Assembly adopted the Global Action Plan on antimicrobial resistance. https://factrail.ai/facts/wha68-7-global-action-plan-amr-2015. - 2014: WHO issued its first global report on antimicrobial resistance after surveying 114 countries. https://factrail.ai/facts/who-first-global-amr-surveillance-report-2014. ## Methodology https://factrail.ai/methodology Canonical: https://factrail.ai/drivers/antimicrobial-resistance